MARKET

CALT

CALT

Calliditas Therapeutics AB
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.60
+1.57
+7.13%
Closed 16:00 08/14 EDT
OPEN
24.16
PREV CLOSE
22.03
HIGH
24.39
LOW
23.51
VOLUME
12.02K
TURNOVER
--
52 WEEK HIGH
28.38
52 WEEK LOW
19.00
MARKET CAP
546.29M
P/E (TTM)
-98.6622
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CALT stock price target is 39.50 with a high estimate of 43.00 and a low estimate of 36.00.

EPS

CALT News

More
Calliditas Therapeutics reports Q2 results
Calliditas Therapeutics (CALT): Q2 GAAP EPS of -SEK1.50.Cash balance of SEK 1,459.6M. Shares +10.3% PM.Press Release
Seekingalpha · 11h ago
Calliditas to buy controlling stake in Genkyotex
Calliditas Therapeutics ([[CALT]] -0.3%) has agreed to acquire a 62.7% interest in Genkyotex through an off-market block trade of 7.2M Genkyotex, for €20.3M at €2.80/share.The deal adds late-stage orphan pipeline asset and platform
Seekingalpha · 1d ago
Calliditas to buy controlling stake in Genkyotex
Calliditas Therapeutics ([[CALT]] -0.3%) has agreed to acquire a 62.7% interest in Genkyotex through an off-market block trade of 7.2M Genkyotex, for €20.3M at €2.80/share.The deal adds late-stage orphan pipeline asset and platform
Seekingalpha · 1d ago
Number of shares and votes in Calliditas Therapeutics
During July, Calliditas Therapeutics AB (publ) has issued 706,676 common shares as a result of the exercise of the over-allotment option within the initial public offering on The Nasdaq Global Select Market and the concurrent private placement of common shares
PR Newswire · 07/31 10:27
The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22)
Benzinga · 07/23 12:25
The Daily Biotech Pulse: Opko Wins CDC Contract, Novartis Lowers Guidance, Pieris Study Placed On Partial Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20)
Benzinga · 07/21 11:59
Why Calliditas Therapeutics Stock Trading Higher Today
Calliditas Therapeutics (NASDAQ: CALT) shares are trading higher on Tuesday after Jefferies initiated coverage on the stock with a Buy rating and a price target of $44 per share.
Benzinga · 06/30 15:26
Morning Market Stats in 5 Minutes
Movers Indices • S&P 500 ETF (NYSE:SPY) fell 0.19% to $303.99. • Nasdaq ETF (NASDAQ:QQQ) fell 0.01% to $242.82. • Dow Jones Industrial Average ETF (NYSE:DIA) decreased 0.45% to $254.97.
Benzinga · 06/30 14:23

Industry

Pharmaceuticals
-0.32%
Pharmaceuticals & Medical Research
-0.38%

Hot Stocks

Symbol
Price
%Change

About CALT

Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.
More

Webull offers kinds of Calliditas Therapeutics AB stock information, including NASDAQ:CALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CALT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CALT stock methods without spending real money on the virtual paper trading platform.